HC Wainwright Analysts Give Adamis Pharmaceuticals (ADMP) a $7.00 Price Target

HC Wainwright set a $7.00 price target on Adamis Pharmaceuticals (NASDAQ:ADMP) in a research report released on Monday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

ADMP has been the subject of a number of other reports. Maxim Group set a $5.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, February 14th. B. Riley reissued a buy rating on shares of Adamis Pharmaceuticals in a report on Wednesday, March 14th. Zacks Investment Research raised shares of Adamis Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 16th. ValuEngine raised shares of Adamis Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, May 2nd. Finally, Raymond James set a $7.00 price target on shares of Adamis Pharmaceuticals and gave the company a buy rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Adamis Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $7.88.

Adamis Pharmaceuticals opened at $4.35 on Monday, Marketbeat.com reports. The stock has a market cap of $136.06 million, a PE ratio of -4.83 and a beta of 0.36. Adamis Pharmaceuticals has a 52 week low of $4.05 and a 52 week high of $4.40. The company has a quick ratio of 1.57, a current ratio of 1.88 and a debt-to-equity ratio of 0.07.

Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The business had revenue of $3.18 million for the quarter, compared to the consensus estimate of $3.34 million. Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%. equities research analysts expect that Adamis Pharmaceuticals will post -0.74 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. B. Riley Financial Inc. bought a new position in Adamis Pharmaceuticals during the 4th quarter valued at about $1,022,000. Northern Trust Corp lifted its holdings in Adamis Pharmaceuticals by 50.7% during the 1st quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock valued at $489,000 after purchasing an additional 46,924 shares during the last quarter. Virtu Financial LLC bought a new position in Adamis Pharmaceuticals during the 4th quarter valued at about $442,000. Dimensional Fund Advisors LP bought a new position in Adamis Pharmaceuticals during the 1st quarter valued at about $244,000. Finally, Wells Fargo & Company MN lifted its holdings in Adamis Pharmaceuticals by 1,050.3% during the 4th quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after purchasing an additional 25,732 shares during the last quarter. 11.50% of the stock is owned by hedge funds and other institutional investors.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply